Abstract
(–)-Verbenone, a monoterpene bicyclic ketone, is a component of the essential oil from rosemary species such as Rosmarinus officinalis L., Verbena triphylla, and Eucalyptus globulus and is used for an herb tea, a spice, and a perfume. In this study, (–)-verbenone was found to be converted to 10-hydroxyverbenone by rat and human liver microsomal cytochrome P450 (P450) enzymes. The product formation was determined by high-performance liquid chromatography with UV detection at 251 nm. There was a good correlation between activities of coumarin 7-hydroxylation and (–)-verbenone 10-hydroxylation catalyzed by liver microsomes of 16 human samples, indicating that CYP2A6 is a principal enzyme in (–)-verbenone 10-hydroxylation in humans. Human recombinant CYP2A6 and CYP2B6 catalyzed (-)verbenone 10-hydroxylation at Vmax values of 15 and 21 nmol/min/nmol P450 with apparent Km values of 16 and 91 μM, respectively. In contrast, rat CYP2A1 and 2A2 did not catalyze (–)-verbenone 10-hydroxylation at all, suggesting that there were species-related differences in the catalytic properties of human and rat CYP2A enzymes in the metabolism of (–)-verbenone. In the rat, recombinant CYP2C11, CYP2B1, and CYP3A2 catalyzed (–)-verbenone 10-hydroxylation with Vmax and Km ratios (ml/min/nmol P450) of 0.73, 0.20, and 0.03, respectively. Male-specific CYP2C11 was a major enzyme in (–)-verbenone 10-hydroxylation by untreated rat livers, and CYP2B1 catalyzed this reaction in liver microsomes of phenobarbital-treated rats. Rat CYP2C12, a female-specific enzyme, did not catalyze (-)verbenone 10-hydroxylation. These results suggest that human CYP2A6 and rat CYP2C11 are the major catalysts in the metabolism of (–)-verbenone by liver microsomes and that there are species-related differences in human and rat CYP2A enzymes and sex-related differences in male and female rats in the metabolism of (–)-verbenone.
Footnotes
-
↵1 Abbreviations used are: P450, cytochrome P450; HPLC, high-performance liquid chromotography; PB, phenobarbital; thioTEPA, triethylenethiophosphoramide.
-
This work was supported in part by grants from the Ministry of Education, Science, and Culture of Japan, and the Ministry of Health and Welfare of Japan.
- Received February 4, 2003.
- Accepted April 25, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|